The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
Twitter chat on coping with cancer
Recently, the National Cancer Institute and the National Institutes of Mental Health co-hosted a Twitter chat on coping with cancer. The discussion focused on the psycho-social aspects of cancer for patients and caregivers across all age groups, and VCU Massey Cancer Center clinical health psychologist, Tamara Orr, Ph.D., M.S., L.C.P., PMHNP-BC, weighed in as the moderator posed a series of questions.
Massey opens clinical trial testing a combination of Viagra and chemo to treat advanced solid tumors
VCU Massey Cancer Center has developed and opened a Phase 1 clinical trial to study the effects of Viagra in combination with chemotherapy to treat patients with progressive, advanced solid tumors. The trial is a result of previous research conducted at Massey by a group of researchers including physician-scientist Andrew Poklepovic, M.D., who is the leading the trial as its principal investigator. Their research demonstrated that regorafenib (trade name Stivarga), a type of chemotherapy, interacts with Viagra (generic name sildenafil), a medication originally developed for erectile dysfunction, to kill tumor cells significantly better than regorafenib alone.
Massey researchers find link between cancer gene and obesity
Recent discoveries suggest that the gene Astrocyte elevated gene-1 (AEG-1) could even be controlled with certain therapies to prevent or reverse obesity and obesity-related cancers.
Massey researcher awarded grant to further develop a novel therapy for neuroblastoma
VCU Massey Cancer Center researcher Anthony Faber, Ph.D., was awarded a $46,000 grant from the Rally Foundation for Childhood Cancer Research and The Truth 365 to support his research to develop a new therapy for neuroblastoma, a rare type of cancer that develops in infants and young children.
Massey welcomes William McGuire as director of the Phase I Solid Tumor Program
VCU Massey Cancer Center welcomes physician-researcher William McGuire III, M.D., as the director of the Phase 1 Solid Tumor Program. Also a medical oncologist and member of the Developmental Therapeutics research program at Massey, McGuire joined the VCU Department of Internal Medicine in fall 2014 as a professor of medicine in the Division of Hematology, Oncology and Palliative Care. An expert in gynecologic cancers and developmental therapeutics, McGuire was instrumental in the development of paclitaxel as part of the standard of care for advanced ovarian cancer.